These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 19907153

  • 1. Deferiprone chelation therapy for thalassemia major.
    Galanello R, Campus S.
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [Abstract] [Full Text] [Related]

  • 2. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, Sau F, Cianciulli P, Maggio A, Galanello R, Farci P.
    Blood Cells Mol Dis; 2010 Aug 15; 45(2):136-9. PubMed ID: 20678715
    [Abstract] [Full Text] [Related]

  • 3. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Aug 15; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 4. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Aug 15; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 5. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Aug 15; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 6. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P.
    J Cardiovasc Magn Reson; 2013 Jan 16; 15(1):1. PubMed ID: 23324167
    [Abstract] [Full Text] [Related]

  • 7. Combined therapy with deferoxamine and deferiprone.
    Kattamis A.
    Ann N Y Acad Sci; 2005 Jan 16; 1054():175-82. PubMed ID: 16339663
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major.
    Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C.
    Haematologica; 2007 Dec 10; 92(12):1599-606. PubMed ID: 18055982
    [Abstract] [Full Text] [Related]

  • 10. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective.
    Galanello R.
    Ther Clin Risk Manag; 2007 Oct 10; 3(5):795-805. PubMed ID: 18473004
    [Abstract] [Full Text] [Related]

  • 11. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A, Zevgaridou E, Tsatra I, Perifanis V, Vlachaki E, Papassotiriou I, Apostolakou F, Athanassiou-Metaxa M.
    J Pediatr Hematol Oncol; 2007 Sep 10; 29(9):598-601. PubMed ID: 17805032
    [Abstract] [Full Text] [Related]

  • 12. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul 10; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 13. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH, Mrkobrada M.
    Hemoglobin; 2014 Jul 10; 38(6):409-21. PubMed ID: 25307964
    [Abstract] [Full Text] [Related]

  • 14. Objectives and mechanism of iron chelation therapy.
    Hershko C, Link G, Konijn AM, Cabantchik ZI.
    Ann N Y Acad Sci; 2005 Jul 10; 1054():124-35. PubMed ID: 16339658
    [Abstract] [Full Text] [Related]

  • 15. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug 10; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 16. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E, Canatan D, Ormeci AR, Vural H, Aylak F.
    J Trace Elem Med Biol; 2013 Apr 10; 27(2):109-11. PubMed ID: 23164519
    [Abstract] [Full Text] [Related]

  • 17. The controversial role of deferiprone in the treatment of thalassemia.
    Richardson DR.
    J Lab Clin Med; 2001 May 10; 137(5):324-9. PubMed ID: 11329529
    [Abstract] [Full Text] [Related]

  • 18. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 May 10; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 19. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan 10; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA.
    N Engl J Med; 1998 Aug 13; 339(7):417-23. PubMed ID: 9700174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.